Use of anti-thyroid drugs in euthyroid pregnant women with previous Graves' disease

Clinical and Investigative Medicine

Volumn 28, Issue 3, 2005, Pages 127-131

  McNab, Tammy ^a,b   Ginsberg, Jody ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHYROID AGENT; PROPYLTHIOURACIL; THIAMAZOLE; THYROTROPIN RECEPTOR ANTIBODY;

BIOASSAY; BLOOD SAMPLING; CLINICAL ARTICLE; CORDOCENTESIS; CRANIOFACIAL SYNOSTOSIS; FEMALE; GRAVES DISEASE; HUMAN; PRIORITY JOURNAL; RADIOIODINATION; REVIEW; RISK ASSESSMENT;

ADULT; ANTITHYROID AGENTS; BIOLOGICAL ASSAY; DATABASES, BIBLIOGRAPHIC; EMBRYO; FEMALE; FETAL MONITORING; GRAVES DISEASE; HUMANS; HYPERTHYROIDISM; METHIMAZOLE; PREGNANCY; PREGNANCY COMPLICATIONS; THYROID GLAND;

EID: 22144438710     PISSN: 0147958X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Mestman J. Hyperthyroidism in pregnancy. Endocrinol Metab Clin North Am 1998;27:127-49.
2. Zakarija M, McKenzie JM, Hoffman WH. Prediction and therapy of intrauterine and late-onset neonatal hyperthyroidism. J Clin Endocriol Metab 1986;62:368-71.
3. Zakarija M, McKenzie JM. Pregnancy-associated changes in the thyroid- stimulating antibody of Graves' disease and the relationship to neonatal hyperthyroidism. J Clin Endocrinol Metab 1983;57:1036-40.
4. Matsuda T, Momoi T, Akaishi K et al. Transient neonatal hyperthyroidism and maternal thyroid stimulating immunoglobulins. Arch Dis Child 1988;63:205-207.
5. Matsuda N, Fujieda K, Iida Y et al. TSH-receptor antibodies in mothers with Graves' disease and outcome in their offspring. Lancet 1988;2:14-7.
6. Daneman D, Howard NH. Neonatal thyrotoxicosis: Intellectual impairment and craniosynostosis in later years. J Pediatr 1980;97:257-9.
7. Cove DH, Johnston P. Fetal hyperthyroidism: Experience of treatment in four siblings. Lancet 1985;1:430-2.
8. Perelman AH, Clemons RD. The fetus in maternal hyperthyroidism. Thyroid 1992;2:225-8.
9. Davies TF. Thyroid immunology of the postpartum period. Thyroid 1999;9:675-84.
10. Laurberg P, Nygaard B, Glinoer D, Grussendorf M, Orgiazzi J. Guidelines for TSH-receptor antibody measurements in pregnancy: Results of an evidence-based symposium organized by the European Thyroid Association. Eur J Endocrinol 1998;139:584-6.
11. Wallace C, Couch R, Ginsberg J. Fetal thyrotoxicosis: A case report and recommendations for prediction, diagnosis and treatment. Thyroid 1995;5:125-8.
12. Peleg D, Cada S, Peleg A, Ben-Ami M. The relationship between maternal serum thyroid-stimulating immunoglobulin and fetal and neonatal thyrotoxicosis. Obstet Gynecol 2002;99:1040-1043.
13. Kung AWC, Jones BM. A change from stimulatory to blocking antibody activity in Graves' disease during pregnancy. J Cin Endocrinol Metab 1998;83:514-8.
14. Amino N, Izumi Y, Hidaka Y et al. No increase of blocking type anti-thyrotropin receptor antibodies during pregnancy in patients with Graves' disease. J Clin Endocrinol Metab 2003;88:5871-4.
15. Hashim FA, Creagh FM, Hawrani AE et al. Characterization of TSH antagonist activity in the serum of patients with thyroid disease. Clin Endocrinol (Oxf) 1986;25:275-81
16. Rakover Y, Weiner E, Mosh N, Shalev E. Fetal pituitary negative feedback at early gestational age. Clin Endocrinol (Oxf) 1999;50:809-14
17. Serup J, Petersen S. Fetal thyrotoxicosis in utero. Biol Neonate 1979;35:175-9.
18. Check JH, Rezvani I, Goodner D, Hopper B. Prenatal treatment of thyrotoxicosis to prevent intrauterine growth retardation. Obstet Gynecol 1982;60:122-4.
19. Volpe R, Ehrlich R, Steiner G, Row W. Graves' disease in pregnancy years after hypothyroidism with recurrent passive-transfer neonatal Graves' disease in offspring: Therapeutic considerations. Am J Med 1984;77:572-8.
20. Pekonen F, Teramo K, Makinen T et al. Prenatal diagnosis and treatment of fetal thyrotoxicosis. Am J Obstet Gynecol 1984;150:893-4.
21. Treadwell MC, Sherer DM, Sacks AJ, Ghezzi F, Romero R. Successful treatment of recurrent non-immune hydrops secondary to fetal hyperthyroidism. Obstet Gynecol 1996;87:838-40.
22. Polak M, Leger J, Luton D et al. Fetal cord blood sampling in the diagnosis and the treatment of fetal hyperthyroidism in the offsprings of a euthyroid mother, producing thyroid stimulating immunoglobulins. Ann Endocrinol (Paris) 1997;58:338-42.
23. Ting MK, Hsu BR, Huang YY, Lin JD, Chen TC. Recurrent fetal thyrotoxicosis in a woman with Graves' disease: Case report. Chang Gung Med J 1999;22:492-7.
24. Duncombe GJ, Dickinson JE. Fetal thyrotoxicosis after maternal thyroidectomy. Aus NZ Obstet Gynecol 2001;41:224-7.
25. Roti E, Gnudi A, Braverman LE. The placental transport, synthesis and metabolism of hormones and drugs which affect thyroid function. Endocr Rev 1983;4:131-49
26. Mortimer RH, Cannell GR, Addison RS et al. Methimazole and propylthirouracil equally cross the perfused human term placental lobule. J Clin Endcorinol Metab 1997;82:3099-102.
27. Momotani N, Noh JY, Ishikawa N, Ito K. Effects of propylthirouracil and methimazole on fetal thyroid status in mothers with Graves' hyperthyroidism. J Clin Endocrinol Metab 1997;82:3633-6.
28. Azizi F, Khamseh ME, Bahreynian M, Hedayati M. Thyroid function and intellectual development of children of mothers taking methimazole during pregnancy. J Endocrinol Invest 2002;25:586-9.
29. Geffner DL, Azukizawa M, Hershman JM. Propylthiouracil blocks extrathyroidal conversion of thyroxine to triiodothyronine and augments thyrotropin secretion in man. J Clin Invest 1975;55:224-9.
30. Karlsson FA, Axelsson O, Melhus H. Severe embryopathy and exposure to methimazole in early pregnancy. J Clin Endocrinol Metab 2002;87:947-9
31. Houck JA, Davis RE, Sharma HM. Thyroid-stimulating immunoglobulin as a cause of recurrent intrauterine fetal death. Obstet Gynecol 1988;71:1018-9.
32. Singh PK, Parvin CA, Gronowski AM. Establishment of reference intervals for markers of fetal thyroid status in amniotic fluid. J Clin Endocrinol Metab 2003;88:4175-9.
33. Weiner CP. The role of cordocentesis in fetal diagnosis. Clin Obstet Gynecol 1988;31:285-92.
34. Nachum Z, Rakover Y, Weiner E, Shalev E. Graves' disease in pregnancy: Prospective evaluation of a selective invasive treatment protocol. Am J Obstet Gynecol 2003;189:159-65.
35. Bernaschek G, Yildiz A, Kolankaya A, Stuempflen A, Deutinger J. Complications of cordocentesis in high risk pregnancies: Effects on fetal loss or preterm delivery. Prenat Diagn 1995;15:995-1000.
36. Fisher DA. Fetal thyroid function: Diagnosis and management of fetal thyroid disorders. Clin Obstet Gynecol 1997;30:16-31.
37. Volumenie JL, Polak M, Guibourdenche J et al. Management of fetal goiters: A report of 11 cases in a single perinatal unit. Prenat Diagn 2000;20:799-806.
38. Burrow GN. Maternal-fetal considerations in hyperthyroidism. Clin Endocrinol Metab 1978;7:115-25.
39. Luton D, Fried D, Sibony O et al. Assessment of fetal thyroid function by colored Doppler echography. Fetal Diagn Ther 1997;12:24-7.